Editas Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(amounts in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities | ||
| Net loss | $(160,060) | $(237,093) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 10,000 | 21,417 |
| Depreciation | 5,277 | 5,809 |
| Loss on disposal of fixed assets | 2,193 | 149 |
| Net accretion of discounts on marketable securities | (902) | (5,791) |
| Interest related to sale of future revenues | 6,171 | 2,190 |
| Impairment of held for sale assets | 3,758 | — |
| Other non-cash items, net | (449) | (415) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,090 | (6,079) |
| Prepaid expenses and other current assets | 1,062 | 4,396 |
| Right-of-use assets | 11,584 | 1,126 |
| Other non-current assets | 1,040 | 3,366 |
| Accounts payable | (2,888) | (2,286) |
| Accrued expenses | (13,184) | 11,623 |
| Accrued interest on sale of future revenues | (2,128) | — |
| Deferred revenue | (15,916) | (8,463) |
| Operating lease liabilities | (12,081) | (1,504) |
| Other non-current liabilities | 192 | 1,271 |
| Net cash used in operating activities | (165,241) | (210,284) |
| Cash flow from investing activities | ||
| Purchases of property and equipment | (607) | (8,826) |
| Proceeds from the sale of equipment | 269 | — |
| Purchases of marketable securities | — | (86,217) |
| Proceeds from maturities of marketable securities | 139,006 | 257,189 |
| Net cash provided by investing activities | 138,668 | 162,146 |
| Cash flow from financing activities | ||
| Repayment on sale of future revenues | (2,872) | — |
| Proceeds from issuance of common stock from at-the-market equity offering, net | 42,848 | — |
| Proceeds from sale of future revenues, net | — | 55,244 |
| Proceeds from exercise of stock options | 70 | 193 |
| Issuance of common stock under benefit plans | 424 | 590 |
| Net cash provided by financing activities | 40,470 | 56,027 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 13,897 | 7,889 |
| Cash, cash equivalents, and restricted cash, beginning of period | 135,418 | 127,529 |
| Cash, cash equivalents, and restricted cash, end of period | $149,315 | $135,418 |
| Cash and cash equivalents, end of period | 146,645 | 131,541 |
| Restricted cash1 | 2,670 | 3,877 |
| Cash, cash equivalents, and restricted cash, end of period | $149,315 | $135,418 |
| 1As of December 31, 2025 and December 31, 2024, restricted cash of $2,670 and $3,877, respectively, was included in Restricted cash and other non-current assets on the Consolidated Balance Sheets. | ||
|---|---|---|
| Supplemental disclosure of cash and non-cash activities: | ||
| Fixed asset additions included in accounts payable and accrued expenses | $— | $65 |
| Cash paid in connection with operating lease liabilities | 14,968 | 18,447 |
| Remeasurement of operating lease liabilities and right-of-use assets due to lease modification | 766 | 794 |
| Commencement of right-of-use asset | — | 7,844 |
| Modification of right-of-use asset | — | 2,683 |
| Non-cash termination of right-of-use asset | 4,849 | — |
| Cash paid for interest | 2,128 | — |
| Issuance costs associated with the sale of future revenues included in accounts payable and accrued expenses | — | 1,479 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.